SecBot SecBot

MRMD

MARIMED INC.
OTC· Medicinal Chemicals & Botanical Products· Inc. DE· CIK 0001522767 Biotech & Drug Discovery
$0.0535 +0.00 (+2.88%)
Oct 27 4:00 PM ET · prev $0.0520
Median target
$0.2500
+367% · range $0.2500–0.2500
Next earnings
Nov 11
in 15 days · EPS est. −$0.01
1 year
−59.5%
from $0.1320 · Oct 28
30 days
−27.7%
from $0.0740
52-week range
$0.0520–0.1440
−63% from high · low Oct 26
Avg volume 20D
504.8K
Oct 5 spike 1.44M
Short interest
1.0K
0.0%
Days to cover
1.0
at average volume
Insider net
+$4.5K
1 buyer · 0 sellers · since May 22
Filing reports
2
analyzed by SecBot
SecBot read MIXED 2 reports · latest
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL MariMed reported Q1 2026 revenue of $39.5M, up 4.2% YoY from $37.9M, and GAAP net loss narrowed to $3.8M…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • B May 22 1 insider buy $4.5K at $0.0749
  • X Jul 31 Short interest jumps 151.5% to 9.8K
  • X Aug 14 Short interest jumps 124.2% to 22.0K
  • X Sep 15 Short interest jumps 112.7% to 44.7K
  • X Sep 30 Short interest falls 97.8% to 1.0K

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $4.5K at an average $0.0749. No open-market sales. Price is 29% below their cost.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.010 → −$0.010 over 90 days.

  • Short sellersSTEADY

    Short interest 0.0% to 1.0K shares. 1.0 days to cover.

  • TrendDOWNTREND

    25% below its 50-day average. New closing low $0.0520 on Oct 26.

The Street

last action Nov 2023
12-month targets · 1 analysts

Price is below the lowest target. Median implies +367%.Targets as of Jul 18, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2023Zuanic & Associates
INITIATE
INITIATEOverweight
Oct 28, 2022BTIG
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
MRMD Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Aug 12, 2026
Earnings date
MRMD Q2 2026 Earnings Scheduled — 2026-08-12
May 13, 2026
Earnings date
MRMD Q1 2026 Earnings Scheduled — 2026-05-13
Mar 11, 2026
Earnings date
MRMD Q4 2025 Earnings After Market Close — 2026-03-11

Insider ledger

Form 4
$4.5K
bought · 1 insider
$0
sold · 0 insiders
−28.6%
vs their $0.0749 cost
DateInsiderTypeValue
Oct 15, 2026
Crandall Ryan
Chief Commercial Officer
EXERCISE32,812 sh
Oct 15, 2026
Crandall Ryan
Chief Commercial Officer
TAX W/H$577.86
Oct 15, 2026
Pinho Mario
Chief Financial Officer
EXERCISE38,282 sh
Oct 15, 2026
Levine Jon R
President and CEO
EXERCISE30,625 sh
Oct 15, 2026
Levine Jon R
President and CEO
TAX W/H$539.34
Oct 15, 2026
Pinho Mario
Chief Financial Officer
TAX W/H$674.16
Oct 15, 2026
Shaw Timothy
Chief Operating Officer
EXERCISE42,657 sh
Oct 15, 2026
Shaw Timothy
Chief Operating Officer
TAX W/H$751.20

Earnings setup

Estimates
Nov 11
reports in 15 days
−$0.01
EPS estimate, this quarter
0%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.01-$0.01–-$0.01+0.0%$41.2M
Next Q-$0.01-$0.01–-$0.01+0.0%$39.8M
Current FY-$0.04-$0.04–-$0.04+0.0%$162.4M
Next FY-$0.03-$0.03–-$0.03+0.0%$167.6M

Short side

FINRA· Oct 15, 2026
1,000
shares short
0.0%
vs prior settlement
1.0
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Insider
Crandall Ryan acquired via exercise 32,812 shares
Chief Commercial Officer
Oct 15, 2026 Insider
Crandall Ryan surrendered for taxes 9,631 shares
Chief Commercial Officer @ $0.0600 ($577.86)
Oct 15, 2026 Insider
Pinho Mario acquired via exercise 38,282 shares
Chief Financial Officer
Aug 12, 2026 Earnings calendar
MRMD Q2 2026 Earnings Scheduled — 2026-08-12
May 13, 2026 SEC
MariMed reported Q1 2026 revenue of $39.5M, up 4.2% YoY from $37.9M, and GAAP net loss narrowed to $3.8M from $5.5M…
8-K — Impact 4/10
Mar 11, 2026 SEC
Analysis based on filing metadata only — document content was unavailable. The filing is an 8-K for Marimed Inc…
8-K — Impact 4/10

SecBot reports

2 filings · 0 bullish · 0 bearish · 2 neutral
All MRMD filing & press-release reports (2)